HY 006
Alternative Names: HY-006; HY-006B7; HY-006B7 inhaledLatest Information Update: 04 Feb 2025
At a glance
- Originator Helperby Therapeutics
- Class Antibacterials; Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 03 Feb 2025 HY 006 is still in preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (Inhalation) (Helperby Therapeutics pipeline, February 2025)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (Inhalation)
- 16 Jun 2020 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (Inhalation), before June 2020 (Helperby Therapeutics pipeline, June 2020)